Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Consultations on compound monograph documents — page 3

51 consultations on documents of this type.

Consultations

51 documents · page 3 of 3
  • CEI-CP-055ClosedCompound monograph14 Jul 2024 – 13 Aug 2024

    Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    7 submissions
  • CEI-CP-058ClosedCompound monograph07 May 2024 – 02 Jul 2024

    Consultation on the draft monograph for Kisspeptin-10, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for…

    4 submissions
  • CEI-CP-056ClosedCompound monograph29 Apr 2024 – 28 Jun 2024

    Consultation on the draft monograph for IGF-1 LR3, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for…

    9 submissions
  • CEI-CP-063ClosedCompound monograph16 Apr 2024 – 11 Jun 2024

    Consultation on the draft monograph for LL-37, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that rating…

    6 submissions
  • CEI-CP-070ClosedCompound monograph05 May 2024 – 04 Jun 2024

    Consultation on the draft monograph for Petrelintide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    15 submissions
  • CEI-CP-052ClosedCompound monograph07 Feb 2024 – 07 Apr 2024

    Consultation on the draft monograph for GHRP-6, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that…

    11 submissions2 not accepted
  • CEI-CP-007ClosedCompound monograph07 Jan 2024 – 07 Mar 2024

    Consultation on the draft monograph for BPC-157. The draft records that the Institute identified no completed randomised controlled trial in humans reporting a clinical outcome, and grades the principal assessed outcome at very low…

    8 submissions1 not accepted
  • CEI-CP-053ClosedCompound monograph08 Feb 2024 – 07 Mar 2024

    Consultation on the draft monograph for Glutathione, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the basis for that…

    14 submissions1 not accepted
  • CEI-CP-042ClosedCompound monograph23 Jan 2024 – 05 Mar 2024

    Consultation on the draft monograph for Cagrilintide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    16 submissions
  • CEI-CP-079ClosedCompound monograph25 Jan 2024 – 24 Feb 2024

    Consultation on the draft monograph for Teduglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at moderate certainty and states the basis for…

    7 submissions
  • CEI-CP-064ClosedCompound monograph12 Jan 2024 – 11 Feb 2024

    Consultation on the draft monograph for Maridebart cafraglutide, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at low certainty and states the…

    9 submissions1 not accepted

page 3 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.